Literature DB >> 19406208

The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer.

Francesco Bertolini1, Patrizia Mancuso, Paola Braidotti, Yuval Shaked, Robert S Kerbel.   

Abstract

Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) are currently being investigated in a variety of diseases as markers of vascular turnover or damage and, also in the case of CEPs, vasculogenesis. CEPs appear to have a "catalytic" role in different steps of cancer progression and recurrence after therapy, and there are preclinical and clinical data suggesting that CEC enumeration might be useful to select and stratify patients who are candidates for anti-angiogenic treatments. In some types of cancer, CECs and CEPs might be one of the possible hidden identities of cancer stem cells. The definition of CEC and CEP phenotype and the standardization of CEC and CEP enumeration strategies are highly desirable goals in order to exploit these cells as reliable biomarkers in oncology clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406208     DOI: 10.1016/j.bbcan.2009.04.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

2.  Identification of a restriction point at the M/G1 transition in CHO cells.

Authors:  E Hullemann; J J M Bijvelt; A J Verkleij; C T Verrips; J Boonstra
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

3.  Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.

Authors:  Mariangela Manzoni; Sara Mariucci; Sara Delfanti; Bianca Rovati; Monica Ronzoni; Fotios Loupakis; Silvia Brugnatelli; Carmine Tinelli; Eugenio Villa; Alfredo Falcone; Marco Danova
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-15       Impact factor: 4.553

Review 4.  Regeneration of the vascular compartment.

Authors:  M U Becher; G Nickenig; N Werner
Journal:  Herz       Date:  2010-08       Impact factor: 1.443

5.  A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.

Authors:  Katherine M Bell-McGuinn; Carolyn M Matthews; Steffan N Ho; Minal Barve; Lucy Gilbert; Richard T Penson; Ernst Lengyel; Rameshraja Palaparthy; Kye Gilder; Artemios Vassos; William McAuliffe; Sara Weymer; Jeremy Barton; Russell J Schilder
Journal:  Gynecol Oncol       Date:  2011-01-26       Impact factor: 5.482

Review 6.  Endothelial progenitor cells: quo vadis?

Authors:  Matthew R Richardson; Mervin C Yoder
Journal:  J Mol Cell Cardiol       Date:  2010-07-29       Impact factor: 5.000

Review 7.  Isolating and defining cells to engineer human blood vessels.

Authors:  P J Critser; S L Voytik-Harbin; M C Yoder
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

8.  Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.

Authors:  Ehud Segal; Huaizhong Pan; Liat Benayoun; Pavla Kopečková; Yuval Shaked; Jindřich Kopeček; Ronit Satchi-Fainaro
Journal:  Biomaterials       Date:  2011-03-22       Impact factor: 12.479

9.  Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples.

Authors:  T R Cawthorn; E Amir; R Broom; O Freedman; D Gianfelice; D Barth; D Wang; I Holen; S J Done; M Clemons
Journal:  Clin Exp Metastasis       Date:  2009-08-21       Impact factor: 5.150

10.  Dynamic shear stress regulation of inflammatory and thrombotic pathways in baboon endothelial outgrowth cells.

Authors:  Randall F Ankeny; Monica T Hinds; Robert M Nerem
Journal:  Tissue Eng Part A       Date:  2013-03-19       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.